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Tackling cervical cancer 
in Europe amidst the 
COVID-19 pandemic
According to estimates for 2018,1 
approximately 33 000 cases of cervical 
cancer occurred and 15 000 people 
died from the disease in Europe 
(see map in appendix). Human 
papillomavirus (HPV) vaccine coverage 
is relatively low in countries with 
the highest incidence and screening 
performance is heterogeneous among 
European countries. Cytological 
screening followed by treatment of 
screen-detected cervical lesions has 
resulted in substantial decreases in the 
burden of cervical cancer in western 
and northern Europe; but in eastern 
Europe, cervical cancer incidence and 
mortality remain comparatively high.2
Today, new powerful tools are 
available for primary and secondary 
prevention of cervical cancer, among 
which prophylactic HPV vaccines, and 
screening using validated HPV tests for 
women—including some tests that can 
be applied on self-collected samples, a 
strategy that might be used to reach 
underscreened populations.3
In May, 2018, the WHO Director 
General launched a call to eliminate 
cervical cancer by vaccinating at least 
90% of girls by age 15 years, by offering 
screening at least twice in a lifetime 
to 70% or more of the target age 
populations and treat more than 90% of 
women with screen-detected lesions.
Recently, a large group of experts 
from diverse professional societies 
and cancer organisations supporting 
WHO’s call to eliminate cervical 
cancer, proposed a series of concerted 
actions to implement organised 
integrated HPV vaccination and 
HPV-based screening, and requested 
European health authorities to 
endorse the principles of the WHO 
elimination initiative, mobilise 
resources to update evidence-based 
guidelines, and translate them into 
quantified and monitored preventive 
activities.4
However, in the first half of 2020, 
due to the dramatic COVID-19 
pandemic, cervical cancer prevention 
activities have been disrupted in many 
European countries. We are concerned 
and urge the public health community 
to maintain sufficient resources to 
sustain HPV vaccination and cancer 
screening in the future. 
Importantly, the COVID-19 pandemic 
might also generate opportunities 
for more efficient prevention, by 
promoting more cost-effective, 
evidence-based protocols, by focusing 
on women who are at high-risk, 
extending HPV testing on self-collected 
samples, and discouraging inefficient 
policies, such as screening with two 
tests. We welcome the un precedented 
collaborations between the cancer and 
infectious disease communities, who 
have been working jointly to tackle the 
spread of the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
by applying the experience of HPV test 
evaluation to protocols for comparing 
and validating SARS-CoV-2 assays and 
by bringing modellers together in the 
COVID-19 and Cancer Taskforce Global 
Modelling Consortium.
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